Dicerna Pharmaceuticals (DRNA) Upgraded to “Buy” at ValuEngine

Dicerna Pharmaceuticals (NASDAQ:DRNA) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday.

Other equities research analysts have also recently issued research reports about the company. Zacks Investment Research raised Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a research report on Tuesday, March 12th. BidaskClub raised Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, January 5th. SunTrust Banks upped their target price on Dicerna Pharmaceuticals to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, March 13th. B. Riley upped their target price on Dicerna Pharmaceuticals from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, March 13th. Finally, Leerink Swann initiated coverage on Dicerna Pharmaceuticals in a research report on Tuesday, November 27th. They set an “outperform” rating and a $24.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $21.78.

Dicerna Pharmaceuticals stock traded up $0.43 during trading hours on Thursday, reaching $14.04. 263,649 shares of the company were exchanged, compared to its average volume of 574,131. The stock has a market capitalization of $929.02 million, a P/E ratio of -11.70 and a beta of 2.40. Dicerna Pharmaceuticals has a 12 month low of $8.71 and a 12 month high of $17.98.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The company had revenue of $1.54 million for the quarter, compared to the consensus estimate of $8.38 million. Dicerna Pharmaceuticals had a negative return on equity of 53.27% and a negative net margin of 1,438.68%. Analysts expect that Dicerna Pharmaceuticals will post -0.99 EPS for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Dicerna Pharmaceuticals by 512.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,459 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 2,894 shares during the period. Legal & General Group Plc boosted its position in shares of Dicerna Pharmaceuticals by 38.7% in the fourth quarter. Legal & General Group Plc now owns 9,186 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 2,561 shares during the period. Bank of America Corp DE boosted its position in shares of Dicerna Pharmaceuticals by 30.3% in the fourth quarter. Bank of America Corp DE now owns 10,596 shares of the biopharmaceutical company’s stock valued at $113,000 after acquiring an additional 2,465 shares during the period. TD Asset Management Inc. bought a new stake in shares of Dicerna Pharmaceuticals in the fourth quarter valued at approximately $169,000. Finally, State Board of Administration of Florida Retirement System boosted its position in shares of Dicerna Pharmaceuticals by 19.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 18,234 shares of the biopharmaceutical company’s stock valued at $195,000 after acquiring an additional 3,024 shares during the period. 92.81% of the stock is owned by institutional investors.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Featured Story: Fiduciary

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.